.png)
German (DE) 
English (US) 
Spanish (ES) 
French (FR) 
Hindi (IN) 
Italian (IT) 
Russian (RU) - Health
- Parenting
- Style and beauty
- Horoscopes
- Shopping
- Food
- Travel
- Autos
- Gift ideas
- Buying guides
- My Portfolio
- News
- Markets
- Stocks: Most Actives
- Stocks: Gainers
- Stocks: Losers
- Trending Tickers
- Futures
- World Indices
- US Treasury Bonds Rates
- Currencies
- Crypto
- Top ETFs
- Top Mutual Funds
- Options: Highest Open Interest
- Options: Highest Implied Volatility
- Sectors
- Basic Materials
- Communication Services
- Consumer Cyclical
- Consumer Defensive
- Energy
- Financial Services
- Healthcare
- Industrials
- Real Estate
- Technology
- Utilities
- Private Companies
- Research
- Personal Finance
- Videos
- Watch Now
- Fantasy
- Daily fantasy
- NFL
- NBA
- MLB
- NHL
- College football
- College basketball
- Soccer
- NFL Draft
- Yahoo Sports AM
- Show all
© 2025 All rights reserved.
Enliven price target lowered to $27 from $36 at JonesResearch
TipRanks
Sat, May 17, 2025, 12:40 PM 1 min read
In This Article:
JonesResearch analyst Soumit Roy lowered the firm’s price target on Enliven (ELVN) to $27 from $36 and keeps a Buy rating on the shares. The company’s abstract from the Phase 1 late line chronic myeloid leukemia trial with ELVN-001 “was met with a lukewarm initial stock reaction that weakened over time,” the analyst tells investors in a research note. The firm says that even though ELVN-001 showed efficacy and safety profile inline with the September 2024 update with two-times the patient population, the market treated the stock with a sell on news approach. Jones sees ELVN-001 performing at least inline with Novartis’ Scemblix.
Confident Investing Starts Here:
-
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
-
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELVN:
Disclaimer & DisclosureReport an Issue
-
Enliven Therapeutics’ ELVN-001: Promising Competitor in the $3 Billion Late Line CML Market
-
Enliven Therapeutics Reports Q1 Results and Pipeline Progress
-
Enliven price target raised to $40 from $39 at H.C. Wainwright
-
Enliven Therapeutics: Strategic Focus and Promising Developments Justify Buy Rating
-
Positive Buy Rating for Enliven Therapeutics Driven by Promising Phase 1 Results of ELVN-001 in CML
Terms and Privacy Policy
Comments